Access count of this item: 2121

Files in This Item:
File Description SizeFormat 
57_291.pdf889.26 kBAdobe PDFView/Open
Title: 去勢抵抗性前立腺癌に対するFlutamideを用いたアンチアンドロゲン交替療法
Other Titles: Alternative Antiandrogen Therapy with Flutamide in Patients with Castration-Resistant Prostate Cancer : A Single Center Experience
Authors: 高田, 剛  KAKEN_name
石津谷, 祐  KAKEN_name
岡田, 宜之  KAKEN_name
植田, 知博  KAKEN_name
井上, 均  KAKEN_name
原, 恒男  KAKEN_name
Author's alias: Takada, Tsuyoshi
Ishizuya, You
Okada, Takayuki
Ueda, Tomohiro
Inoue, Hitoshi
Hara, Tsuneo
Keywords: Castration-resistant prostate cancer
Alternative antiandrogen therapy
Flutamide
Issue Date: Jun-2011
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 57
Issue: 6
Start page: 291
End page: 295
Abstract: Alternative Antiandrogen Therapy with Flutamide in Patients with Castration-Resistant Prostate Cancer : A Single Center Experience We analyzed the clinical effects of flutamide (FLT) as a second-line agent for maximum androgen blockade (MAB) in patients with castration-resistant prostate cancer who received bicalutamide (BCL) as the first-line MAB agent. This study included 44 cases with progressive prostate cancer who had relapsed after first-line MAB, with BCL at 80 mg/day. After checking for antiandrogen withdrawal syndrome (AWS), they were given FLT at 375 mg/day as second-line MAB. A partial response (prostate-specific antigen [PSA] decline ≧50%) and no change (PSA decline of 0-50% or increase <25%) by second-line MAB with FLT were achieved in 34.1% (15/44) and 25.0% (11/44), respectively. The median duration of PSA response was 8.2+/−4.5 months. In multivariate analysis, Gleason score (≦7 vs ≧8), the first-line response (CR vs PR+NC), and the second-line response (PR+NC vs PD) were significantly predictive of cause-specific survival from first-line hormonal therapy relapse to cancer death. Our results confirm previous findings that alternative antiandrogen therapy is effective as a second-line hormonal therapy.
Rights: 許諾条件により本文は2012-07-01に公開
URI: http://hdl.handle.net/2433/143307
PubMed ID: 21795830
Appears in Collections:Vol.57 No.6

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.